Friday, September 25, 2015
Researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) have released new data documenting alarming rates of bacteria resistant to last-resort antibiotics that can lead to life-threatening infections across the world. Though wealthy countries still use far more antibiotics per capita, high rates in the low- and middle-income countries where surveillance data now is available—such as India, Kenya and Vietnam—sound a warning to the world.
CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, has launched its U.S. operations in Cambridge, Mass., as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.
Clinical Research Management (ClinicalRM), a full-service CRO with headquarters in Ohio, has announced that the clinical trial evaluating the safety and efficacy of Ebola convalescent plasma (ECP) for the treatment of Ebola virus disease (EVD) in Liberia has commenced. The first donor survivors at the ELWA Hospital 2 unit in Monrovia, Liberia have undergone plasmapheresis. The donated convalescent plasma was transferred to a Liberian patient with EVD in an effort to help them combat this disease. The ClinicalRM trial is being funded through a grant from the Bill & Melinda Gates Foundation.
Fio has received a grant financed by the Bill & Melinda Gates Foundation to adapt its Fionet solution to connect rapid diagnostics and data in the fight against Ebola. Headquartered in Toronto, Canada, Fio’s solution combines mobile intelligent devices with cloud information services to create a healthcare delivery solution that drives, rather than competes with, data capture.
The Bill & Melinda Gates Foundation, based in Seattle, Wash., will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates also will be evaluated, including the experimental antiviral drug brincidofovir.
The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published by the Access to Medicine Foundation, a nonprofit organization based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries.
The Bill & Melinda Gates Foundation, of Seattle, Wash., has awarded $156 million to PATH, a Seattle-based international nonprofit organization, to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the “accelerating to zero” agenda. Such vaccines would ensure parasite reintroduction is prevented by providing what could be called an “immunological bed net.”